Retatrutide
FDA-approved GLP-1 medications and their generic active ingredients.
Definition
Eli Lilly's investigational triple agonist (LY3437943) targeting GLP-1, GIP, and glucagon receptors. Phase 2 (NEJM 2023, Jastreboff et al.) showed up to 24.2% body weight reduction at 48 weeks at the highest dose. The first phase 3 readout, TRIUMPH-4 (Dec 2025), reported 28.7% mean weight loss in adults with obesity and knee osteoarthritis. Not yet FDA-approved.
Retatrutide: Lilly's triple agonist evidence →
Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.
Related terms in Drugs and brands
Looking for more depth?
- Retatrutide: Lilly's triple agonist evidence
- Browse the full GLP-1 glossary (51 terms across 8 categories)
- Research articles — primary-source deep dives
- Tools and calculators
- Compare GLP-1 telehealth providers